Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if cetuximab can help to control the
disease in patients who have recurrent endometrial cancer.
Primary Objective:
1. To determine the overall disease control rate of cetuximab in patients with progressive or
recurrent endometrial cancer.
Secondary Objectives:
1. To determine the duration of disease control, time to disease progression, and survival
of this cohort of patients.
2. To determine the nature and degree of toxicity of cetuximab in this cohort of patients.
3. To correlate biologic markers with response to therapy if tissue is available.